Retatrutide vs Tirzepatide vs Semaglutide: Compared

Research-informed explainer — last updated 2026-04-11

Semaglutide, tirzepatide, and retatrutide represent three generations of weight-loss medication, each adding receptor targets that produce incrementally larger weight reductions. Semaglutide and tirzepatide are FDA-approved and commercially available. Retatrutide is still in phase 3 trials. Understanding the differences helps patients and clinicians have a more informed conversation about what is available today and what may arrive soon.

This explainer draws on peer-reviewed research from three endocrinologists listed in the Convene directory. Their published work spans liraglutide trials that established the first-generation benchmark (Bode), the STEP-1 and SELECT trials that defined semaglutide's efficacy and cardiovascular profile (Lingvay), and the ADA/EASD 2022 consensus that frames how these agents fit into treatment hierarchies (Buse).

How GLP-1 agonists work

All three drugs belong to a drug class that includes glucagon-like peptide-1 (GLP-1) receptor agonists. GLP-1 is a hormone released from the gut after eating. It does several things at once: it signals the pancreas to release insulin, tells the liver to slow glucose production, and — crucially for weight loss — reaches receptors in the brain that reduce appetite and slow the rate at which the stomach empties.

When a GLP-1 agonist drug binds to the same receptors that natural GLP-1 activates, it produces those effects in a sustained, amplified way. The result is that people feel full sooner, eat less, and lose weight. That mechanism was first demonstrated convincingly in large trials with liraglutide (Victoza/Saxenda), an early GLP-1 agonist. The LEAD-3 trial established liraglutide as superior to glimepiride for blood sugar control [2], and later weight-focused trials showed about 5–6% body weight reduction — meaningful, but modest compared to what came next [1].

What each drug targets

The three drugs differ in which receptors they activate, and each additional receptor adds a layer of effect.

Semaglutide acts on GLP-1 receptors only. It is a more potent, longer-lasting molecule than liraglutide, designed for once-weekly dosing. At the 2.4 mg weekly dose used for obesity, it produces substantially greater weight loss than first-generation GLP-1 agonists.

Tirzepatide adds a second receptor: GIP (glucose-dependent insulinotropic polypeptide). GIP was long thought to have minimal effect on obesity, but research showed that activating GIP receptors simultaneously with GLP-1 receptors amplifies both insulin secretion and appetite suppression through central nervous system pathways. The combination appears to produce greater weight loss than GLP-1 stimulation alone.

Retatrutide adds a third receptor on top of GLP-1 and GIP: the glucagon receptor. Glucagon normally raises blood sugar and increases energy expenditure. Activating glucagon receptors in fat and liver tissue boosts the rate at which the body burns energy. Adding this pathway to dual GLP-1/GIP stimulation is the hypothesis behind retatrutide's substantially larger weight loss numbers in early trials. The trade-off is that glucagon receptor activation can raise blood sugar — which the GLP-1 component counteracts — and the full safety profile at scale is still being established.

At a glance

How much weight loss can patients expect?

The clearest way to understand the progression of these drugs is to look at the percentage of body weight lost in their pivotal trials — keeping in mind these are population averages, and individual results vary.

Semaglutide at 2.4 mg weekly produced an average of 14.9% body weight reduction over 68 weeks in the STEP-1 trial, a large randomized controlled trial in adults with obesity but without diabetes [3]. That was compared to 2.4% in the placebo group, and the difference was highly significant. For someone weighing 250 pounds, 14.9% is roughly 37 pounds.

Tirzepatide at its highest dose (15 mg weekly) produced 20.9% weight reduction in SURMOUNT-1 in adults without diabetes, and 15.7% in SURMOUNT-2, which enrolled adults with type 2 diabetes — a population that typically loses less weight on these agents [4]. Tirzepatide's advantage over semaglutide in head-to-head comparisons has not been established in a prospective randomized trial (the SURMOUNT-5 trial is underway), but the magnitude of the phase 3 results suggests a meaningful difference at higher doses.

Retatrutide produced approximately 24.2% body weight reduction at 48 weeks in a phase 2 trial published in the New England Journal of Medicine in 2023, in adults with obesity. That figure comes from the highest dose tested (12 mg). Phase 2 trials are smaller and shorter than phase 3, and results sometimes do not hold up at scale. Phase 3 trials are ongoing, and the drug is not yet approved.

The historical context matters here. Liraglutide, the first-generation GLP-1 agonist, produced roughly 5–6% body weight reduction in its pivotal trials [1, 2]. The jump from 5% to 15%, and potentially to 24%, over roughly a decade of incremental receptor-targeting represents an unusually rapid advance for a drug class.

Cardiovascular evidence: who has the most data?

For patients with obesity and existing cardiovascular disease, the cardiovascular outcomes data matters as much as weight loss numbers.

Semaglutide is the only drug in this group with a completed large cardiovascular outcomes trial (CVOT) in people with obesity who do not have diabetes. The SELECT trial enrolled more than 17,000 adults with preexisting cardiovascular disease and overweight or obesity. After a mean follow-up of nearly 40 months, semaglutide reduced the composite endpoint of cardiovascular death, nonfatal heart attack, and nonfatal stroke by 20% compared to placebo [5]. This trial was not designed to determine whether the cardiovascular benefit came from weight loss or a direct drug effect — that question is unresolved — but the outcome is clinically meaningful.

Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is underway but not yet completed. There is no completed large CVOT for retatrutide. Clinicians treating patients with significant cardiovascular risk have more evidence to support semaglutide than the newer agents at this time, which the ADA/EASD 2022 consensus notes as a factor in positioning GLP-1 agonists with established CVOT data for high-risk patients [6].

Side effects across all three drugs

The side effect profile is broadly similar across the class because all three drugs activate the GLP-1 receptor.

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are most common when starting treatment or increasing the dose, and they typically improve over several weeks. Slow dose escalation — starting at a low dose and increasing monthly — is the standard approach to managing GI side effects.

Less common but more serious concerns include:

• Pancreatitis: All GLP-1 agonists carry a warning about acute pancreatitis. The absolute risk appears low, but persistent, severe abdominal pain warrants prompt evaluation.
• Gallbladder disease: Rapid weight loss increases the risk of gallstones. GLP-1 agonists may slow gallbladder emptying, adding to that risk.
• Heart rate increase: All three drugs can raise resting heart rate by a few beats per minute. The clinical significance of this in most patients is uncertain.
• Muscle loss: Weight loss from any cause includes some lean mass. Adding resistance training during treatment is commonly recommended to preserve muscle.
• Retatrutide-specific: The addition of glucagon receptor agonism raises a theoretical concern about blood sugar in non-diabetic users. Phase 2 data did not show significant hyperglycemia, but longer-term safety at phase 3 scale is still being characterized.

None of the three drugs should be used in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. The black box warning on the label reflects rodent studies showing thyroid C-cell tumors at high doses; the relevance to humans at clinical doses is unclear, but the contraindication stands.

Availability and approval status

Semaglutide (Ozempic for diabetes, Wegovy for obesity) and tirzepatide (Mounjaro for diabetes, Zepbound for obesity) are both FDA-approved and commercially available in the United States. Access has been constrained by supply shortages and cost, but both are obtainable through standard prescribing channels.

Retatrutide is not FDA-approved and is not commercially available. It is being evaluated in phase 3 clinical trials as of 2024. If phase 3 results replicate the phase 2 findings, it could reach FDA review in the next few years, but no approval timeline is public.

Orforglipron, an oral non-peptide GLP-1 receptor agonist, is also in phase 3 trials. Its potential advantage is a pill formulation rather than a weekly injection, though weight loss data are still maturing.

Cost and insurance coverage

Both approved drugs are expensive without insurance. List prices for Wegovy and Zepbound exceed $1,000 per month. Coverage varies substantially by plan: Medicare did not cover obesity drugs historically, though this has been changing under new federal policy. Many commercial plans cover one or both drugs with prior authorization. Manufacturer savings programs can reduce out-of-pocket costs for commercially insured patients.

For patients who have been on semaglutide and find coverage, cost, or efficacy inadequate, tirzepatide is a reasonable next conversation — particularly given the larger average weight loss at the highest doses. Retatrutide, if approved, would likely enter at a similar or higher price point.

Questions to ask your endocrinologist

• Which of the approved GLP-1 medications is right for my specific combination of weight, diabetes status, cardiovascular history, and insurance coverage?
• If I have already tried semaglutide and lost less than 10% of my body weight, would tirzepatide be likely to produce a better response for me?
• Am I a candidate for a clinical trial of retatrutide or another next-generation agent?
• How should I adjust diet and exercise to preserve muscle mass while losing weight on these medications?
• What signs of pancreatitis or gallbladder problems should prompt me to call the office?
• How long should I plan to stay on this medication — is this a lifetime treatment or are there criteria for stopping?

The bottom line

The GLP-1 receptor agonist class has transformed obesity treatment over the past decade, moving from modest 5–6% weight reduction with liraglutide to an average of nearly 15% with semaglutide, over 20% with tirzepatide at the highest dose, and potentially 24% or more with retatrutide in early-phase data. Each step forward has come from adding receptor targets that amplify appetite suppression and energy expenditure.

For most patients today, the practical choice is between semaglutide and tirzepatide. Semaglutide has a larger evidence base, including the only completed large CVOT in non-diabetic obesity. Tirzepatide produces greater average weight loss at its highest dose. Retatrutide may offer still larger weight loss if phase 3 trials succeed, but it is years away from being prescribable.

If you have struggled to lose weight or have not achieved adequate results on one of these medications, the conversation to have is with an endocrinologist who follows this rapidly moving literature. The right drug depends on your weight loss goal, cardiovascular risk, diabetes status, and what your insurance will cover.